Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Review

Diagnostic value of alpha-l-fucosidase for hepatocellular carcinoma: a meta-analysis

Authors: Yuling Gan, Qiuzhen Liang, Xinghua Song

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

Alpha-fetoprotein (AFP) is the primary marker for detecting hepatocellular carcinoma (HCC) and has been used widely in the clinic, but AFP is a biomarker characterized by poor sensitivity and specificity. Alpha-l-fucosidase (AFU) has been proposed as a tumor marker for diagnosis of HCC in many studies. However, conclusions of its diagnostic value are inconsistent. The current review aimed to evaluate the diagnostic value of AFU for HCC. After systematic review of 12 related studies, sensitivity, specificity, and diagnostic odds ratio (DOR) were pooled using random-effect models. Summary receiver operating characteristic (sROC) curve analysis was used to summarize the overall test performance. The pooled sensitivity for AFU was 0.72 (95 % confidence interval (CI) 0.69–0.76), while the pooled specificity was 0.78 (95 % CI 0.74–0.81). DOR was 10.26 (95 % CI 5.99–17.59), and the area under the curve (AUC) was 0.8125. AFU had great value for the diagnosis of HCC as a serum marker.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed
2.
Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4(3):252–61.CrossRefPubMed
3.
4.
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 \ 1):S35–50.CrossRefPubMed
5.
Bertino G, Ardiri A, Malaguarner M, et al. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39(4):410–33.CrossRefPubMed
6.
Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol. 2012;39(4):434–9.CrossRefPubMed
7.
Ba MC, Long H, Tang YQ, Cui SZ. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int J Clin Exp Pathol. 2012;5(9):874–81.PubMedPubMedCentral
8.
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16(4):418–24.CrossRefPubMedPubMedCentral
9.
10.
Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;10:3–25.
11.
Whiting PF, Rutjes AW, Westwood ME. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRefPubMed
12.
13.
Chen K, Zhang H, Zhang LN, et al. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma. World J Gastroenterol. 2013;19(20):3143–9.CrossRefPubMedPubMedCentral
14.
Wang JJ, Cao EH. Rapid kinetic rate assay of the serum alpha-l-fucosidase in patients with hepatocellular carcinoma by using a novel substrate. Clin Chim Acta. 2004;347(1–2):103–9.CrossRefPubMed
15.
Ishizuka H, Nakayama T, Matsuoka S, et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-l-fucosidase activity. Intern Med. 1999;38(12):927–31.CrossRefPubMed
16.
Giardina MG, Matarazzo M, Morante R, et al. Serum alpha-l-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer. 1998;83(12):2468–74.CrossRefPubMed
17.
Hutchinson WL, Du MQ, Johnson PJ, Williams R. Fucosyltransferases: differential plasma and tissue alterations inhepatocellular carcinoma and cirrhosis. Hepatol. 1991;13(4):683–8.
18.
Zheng T, Ren ZY. Activities of serum enzymes in patients with viral hepatitis B, posthepatitic cirrhosis and hepatocellular carcinoma. Chin Med J (Engl). 1990;103(9):729–34.
19.
Yamamoto K, Yanagita T, Watanabe N, et al. The clinical significance of serum alpha-l-fucosidase assay in hepatocellular carcinoma. Fukuoka Igaku Zasshi. 1988;79(6):463–8.PubMed
20.
Deugnier Y, David V, Brissot P, et al. Serum alpha-l-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology. 1984;4(5):889–92.CrossRefPubMed
21.
Bukofzer S, Stass PM, Kew MC, et al. Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks. Br J Cancer. 1989;59(3):417–20.CrossRefPubMedPubMedCentral
22.
El-Houseini ME, Mohammed MS, Elshemey WM, et al. Enhanced detection of hepatocellular carcinoma. Cancer Control. 2005;12(4):248–53.PubMed
23.
El-Houseini ME. Serum alpha-l-fucosidase enzyme activity as a marker for hepatocellular carcinoma: comparison with AFU using ROC analysis. J Egyptian Nat Canc Inst. 2001;13:277–83.
24.
El-Tayeh SF, Hussein TD, El-Houseini ME, et al. Serological biomarkers of hepatocellular carcinoma in Egyptian patients. Dis Markers. 2012;32(4):255–63.CrossRefPubMedPubMedCentral
25.
Fawzy Montaser M, Amin Sakr M, Omar KM. Alpha-l-fucosidase as a tumour marker of hepatocellular carcinoma. Arab J Gastroenterol. 2012;13(1):9–13.CrossRefPubMed
26.
Giardina MG, Matarazzo M, Varriale A, et al. Serum alpha-l-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. Cancer. 1992;70(5):1044–8.CrossRefPubMed
27.
Hutchinson WL, Johnson PJ, Du MQ, et al. Serum and tissue alpha-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. Clin Sci (Lond). 1991;81(2):177–82.
28.
Marotta F, Chui DH, Safran P, Zhang SC. Serum alpha-l-fucosidase. A more sensitive marker for hepatocellular carcinoma? Dig Dis Sci. 1991;36(7):993–7.CrossRefPubMed
29.
Shao Y. Union examination of AFP, AFU, AFPL3 and γ-GT in early diagnosis of primary liver cancer. Academic Journal of Xi’an Jiaotong University. 2009;21(3).
30.
Takahashi H, Saibara T, Iwamura S. Serum a-l-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology. 1994;19(6):1414–7.PubMed
31.
Tangkijvanich P, Tosukhowong P, Bunyongyod P, et al. Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 1999;30(1):110–4.PubMed
32.
Zhu J, Jiang F, Ni HB, et al. Combined analysis of serum gamma-glutamyl transferase isoenzyme II, alpha-l-fucosidase and alpha-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. Exp Ther Med. 2013;5(1):89–94.PubMed
33.
Troost J, van der Heijden MC, Staal GE. Characterisation of alpha-l-fucosidase from two different families with fucosidosis. Clin Chim Acta. 1976;73(2):329–46.CrossRefPubMed
34.
Zielke K, Okada S, O’Brien JS. Fucosidosis: diagnosis by serum assay of a-Lfucosidase. J Lab Clin Med. 1972;79(1):164–9.PubMed
35.
Van Hoof F, Hers HG. The abnormalities of lysosomal enzymes in mucopolysaccharidoses. Eur J Biochem. 1968;7(1):34–44.CrossRefPubMed
36.
Elshemey WM, Desouky OS, Mohammed MS. Characterization of cirrhosis and hepatocellular carcinoma using low-angle x-ray scattering signatures of serum. Phys Med Biol. 2003;48(17):N239–46.CrossRefPubMed
37.
Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4(7):424–32.CrossRefPubMed
38.
Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79(1):16–20.CrossRefPubMed
39.
Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425C:212–20.CrossRef
Metadata
Title
Diagnostic value of alpha-l-fucosidase for hepatocellular carcinoma: a meta-analysis
Authors
Yuling Gan
Qiuzhen Liang
Xinghua Song
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1563-8

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

Lack of association between vitamin D receptor gene ApaI, BsmI, and TaqI polymorphisms and primary biliary cirrhosis risk: a meta-analysis

Research Article

Transforming growth factor beta1 (TGFβ1) polymorphisms and breast cancer risk

Research Article

Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk

Research Article

Genetic association of CHEK2, GSTP1, and ERCC1 with glioblastoma in the Han Chinese population

Review

Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis

Research Article

Clinical significance and biological roles of CARMA3 in human bladder carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits